Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: The alert urged Americans to seek medical help in the event they suffered any "unusual, unexplained physical symptoms or events, auditory or sensory phenomena, or other health concerns." The alert comes as a U.S. medical team is screening more Americans who work at the Guangzhou consulate. A previous case in Guangzhou, disclosed last month, prompted the tests. The incidents have raised fears the unexplained issues that started in Cuba in 2016 have expanded to other countries. China says it has uncovered no information that could point to a cause. The most recent evacuations followed medical testing that revealed they might have been affected. State Department spokeswoman Heather Nauert said "a number of individuals" had been brought to the U.S. but didn't say how many were affected or evacuated. Friday's alert called for people to be attentive of symptoms including "dizziness, headaches, tinnitus, fatigue, cognitive issues, visual problems, ear complaints and hearing loss, and difficulty sleeping." It urged them "not to attempt to locate the source of any unidentified auditory sensation. Instead, move to a different location." The U.S. government has deemed the Cuba incidents "specific attacks" on American workers but hasn't publicly identified a cause or culprit. Most of the incidents were accompanied by bizarre, unexplained sounds that initially led U.S. investigators to suspect a sonic attack. Asked about the latest incidents, Chinese Foreign Ministry spokeswoman Hua Chunying said Thursday that the U.S. had not formally raised the matter with Beijing. "If the U.S. makes formal contact with us, China will continue necessary investigations in an earnest and responsible manner and maintain close communication and cooperation with the U.S.," Hua said at a regularly scheduled news conference. China earlier said it had looked into the case announced last month but came up with no clues about the cause of the symptoms. A U.S. official, who wasn't authorized to discuss the situation publicly and requested anonymity, said the evacuated American government workers were being brought from China for testing to the University of Pennsylvania. That's where doctors have been treating and studying patients previously evacuated from the U.S. Embassy in Havana. The preliminary findings of the medical reports on the 24 personnel affected in Cuba showed they had sensory and memory problems similar to the brain dysfunction seen with concussions. The Penn team said the patients from Cuba experienced persistent disability though rehabilitation therapy customized for them seemed to help. Canada in April also ordered families of diplomatic staff in Cuba to return home after mysterious health symptoms were detected in 10 Canadians stationed on the island. Canada said the 10 continued to show unexplained brain symptoms and that "medical information raised concerns for a new type of a possible acquired brain injury." In testimony before the Senate Foreign Relations Committee last month about the first case in China, U.S. Secretary of State Mike Pompeo said China had "said all the right things and have demonstrated their willingness to help us identify the vector which led to this medical incident." The China incidents affect one of the most important of the seven U.S. diplomatic outposts in the country. The Guangzhou consulate opened months after the establishment of diplomatic relations between Beijing and Washington in 1979 and moved to its new purpose-built facility in 2013. It serves four southern provinces with a combined population of more than 204 million and processes more than 1 million visa applications of all types annually. It is also the only U.S. diplomatic installation in China authorized to process immigrant visas and handle adoptions. People working in The Canton Place complex, a few kilometers (miles) from the consulate, said Thursday they were just hearing about the incidents, reflecting a lack of coverage in China's entirely state-controlled media. Aled Williams, a British teacher at a kindergarten said Thursday that the reports sounded "sci-fi-ish." "Hard to get my head around how it works," he said. "Better watch myself." Linda Chen, who runs a coffee shop in the area, said she was mystified as to why only certain people seemed to have been affected in an area known for its comfort and safety. "For me I feel it's very strange. But I don't feel that there's something to be very afraid of because it's probably a very special case," Chen said. ___ Associated Press writer Josh Lederman in Washington, D.C. contributed to this report.

Output: US Embassy in China sends new alert for mystery health issue.

Input: Consider Input: Health Secretary Lorenzo Gonzalez said Saturday that officials discovered a cache of urgently needed personal protective equipment at a hospital in the nearby island of Vieques that remains closed since the Category 4 storm hit the U.S. territory in September 2017. He said the equipment includes face masks, gloves, gowns and face shields that were in good condition and would be distributed to health institutions. "They're very useful at this moment," said Gonzalez, who became the island's newest health secretary this week, the third in the span of two weeks. He also said officials recently located a warehouse with medicine and medical equipment worth $4 million donated during Hurricane Maria, and that nearly all of it had expired. He did not provide details about what specific items were found. Puerto Rico has reported 18 deaths related to COVID-19, including that of a nurse, and more than 450 confirmed cases, including several police officers who join health workers in demanding more personal protective equipment. "Police are going the extra mile right now, and the government is not protecting us like it should," said Gregorio Matias, vice president of a police union. The discovery in Vieques outraged many on an island still struggling to recover from Maria and from a series of strong earthquakes that hit Puerto Rico's southern region in recent months. Gonzalez said he has ordered an investigation into why those supplies were abandoned in Vieques. The announcement comes two months after a group of Puerto Ricans discovered and broke into a warehouse filled with emergency supplies in southern Puerto Rico at a time local officials sought urgent help for those affected by a string of earthquakes. Other similar discoveries have been made since Maria hit. Gonzalez said the government still needs other equipment including testing kits and ventilators, noting that there are only 500 available for an island of 3.2 million people with high rates of asthma. "If that's going to be the difference between life and death, people are going to die," he said. "Don't take this lightly." A doctor who leads a COVID-19 government task force has said the U.S. territory needs at least 3,000 ventilators with the anticipated peak in cases expected in early May. Puerto Rico is in the middle of a month long curfew that is one of the strictest in any U.S. jurisdiction and has shuttered non-essential businesses and banned people from going outside unless they have to buy food, medicine or go to the bank.

Output: Puerto Rico discovers protective supply cache amid COVID-19.

Input: Consider Input: The trial results on patients with a gene anomaly known as NTRK fusion, which occurs in less than 1 percent across a range of tumor types, were presented at the annual congress of the European Society for Medical Oncology (ESMO) in Munich on Sunday. Germany's Bayer and U.S. partner Loxo, in turn, released data for their rival compound larotrectinib, which slightly improved on previous high-efficacy readings in an enlarged trial. Traditionally, oncologists have made treatment decisions based on where in the body a tumor started, increasingly helped by the growing knowledge of cancer's complex genetic drivers. Under the tumor-agnostic approach, also known as pan-tumor, drugmakers skip the organ-of-origin perspective and regroup patients based only on signature genetic mutations, but success in real life will depend on the fast spread of comprehensive gene-sequencing tools for tissue samples. Individually, the mutations are so rare that cancer units are seen as unlikely to run dedicated tests for each. Roche's Foundation Medicine supplies the comprehensive kits, competing with Thermo Fisher Scientific and Caris Life Sciences. "It's one of the reasons we acquired Foundation Medicine, to make this comprehensive genomic profiling routine and upfront in the course of the disease," said Daniel O'Day, the head of Roche's Pharmaceuticals division. Loxo's larotrectinib pill, co-developed with Bayer, was last year shown to shrink tumors in 75 percent of patients with the NTRK fusion gene anomaly, occurring in the lung, pancreas, or more than a dozen other organs. On Sunday, the response rate to larotrectinib within an enlarged group of 122 trial participants - up from 55 initially and now spanning 24 tumor types - was shown to be 81 percent. Roche said the readings from the two NTRK fusion trials were not comparable because they are made up of different patient types. Loxo's study, for instance, included some cancers in children, while Roche plans to investigate those separately. The Roche compound is designed to tackle several oncogenic mutations and last month, it unveiled data here on entrectinib pushing back tumors in 77 percent of lung cancer patients with a mutation called ROS1. Merck & Co's Keytruda in May last year became the first drug to win approval for pan-tumor use, though that remains a relatively small market for the mega-selling drug. Bayer and Loxo are testing a second pan-tumor drug, LOXO-195. Roche Pharmaceutical's O'Day welcomed a wider field. "Both things have to happen: You need genomic profiling and you need enough targeted medicines to encourage physicians to make that diagnosis upfront very complete. This is the world we're entering," he said. Though response rates could encourage a race for more such drugs, the need for suitable gene mutations or fusions will be a tall order, said oncologist Ulrik Lassen of Copenhagen's Rigshospitalet, who co-authored the larotrectinib study. "You need to screen a lot of patients to find the needle in the haystack and the method is complicated, costly and time-consuming. When we get better at using these technologies, we can find more oncogenic fusions and companies will be smart enough to find the agents that target them." Roche acquired entrectinib as part of its takeover deal with U.S. cancer drug specialist Ignyta Inc for $1.7 billion, agreed in December last year. Immuno-oncology remains another major business area for Roche, which also released positive results on using its Tecentriq drug in a group of breast cancer patients with a particularly poor prognosis.
Output: Roche takes on Loxo, Bayer in gene-defined cancer class.